Browse the evidence

GLP-1 receptor agonists produced greater weight loss among women (10.9%; 95% CI, 7.0%-14.8%) than men (6.8%; 95% CI, 4.6%-9.0%).

Practitioners should consider gender differences when prescribing GLP-1 receptor agonists for weight loss.

GLP-1-based medications can achieve up to 24% weight loss, aiding in the effective management of obesity and its complications.

Practitioners can consider GLP-1 medications as a viable option for weight management in obese patients.

Semaglutide, a GLP-1 receptor agonist, can lead to weight reductions of up to 15%.

Practitioners should consider the potential effectiveness of semaglutide for weight loss in patients.

Incretin-based therapies induced substantial weight loss, mostly from fat mass.

Practitioners can consider incretin-based therapies as effective options for promoting fat loss in T2D patients.

Broad access to semaglutide would result in 38,950 cardiovascular events avoided and 6,180 deaths avoided over a 10-year period.

Practitioners should consider the significant health benefits of prescribing semaglutide to eligible Medicare patients.

CagriSema is being marketed as a safe and potentially superior medication to lower both Hemoglobin A1c and body weight.

Practitioners may consider CagriSema as a treatment option for patients needing glycemic control and weight management.

Treatment proposals for obesity must be individualized according to phenotyping.

Tailoring obesity treatment plans to individual profiles can enhance effectiveness.

Glucagon-like peptide-1 receptor agonists induce substantial and durable weight loss and improve obesity-related gastrointestinal outcomes.

Practitioners can consider GLP-1 receptor agonists as effective treatments for weight management and gastrointestinal health.

Tirzepatide offers superior glycemic control and weight reduction compared to conventional GLP-1 receptor agonists.

Practitioners may consider Tirzepatide as a more effective option for managing glycemic control and weight in patients with T2DM.

Lifestyle modifications are often the first-line intervention for improving hormonal imbalances and menstrual cycles in women with PCOS.

Clinicians should consider lifestyle modifications as a primary strategy in managing PCOS.

Tirzepatide 10 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 5.3% to 1.2%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Tirzepatide 15 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 4.9% to 1.0%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Two-thirds of respondents reported reduced appetite, food cravings, or body weight.

Practitioners can expect that a significant portion of patients may experience appetite reduction and weight loss with Ozempic.

Semaglutide (Wegovy) has demonstrated unprecedented efficacy in weight reduction, glycaemic control, and cardiovascular protection.

Semaglutide may be a highly effective treatment option for obesity and type 2 diabetes.

Semaglutide is endorsed as a secondary treatment for improving glycemic control in type 2 diabetes mellitus (T2DM).

Practitioners can consider semaglutide as a secondary option for patients with T2DM to improve blood sugar control.

Semaglutide is being investigated for its potential in combating obesity.

Practitioners should stay informed about the potential use of semaglutide for obesity management.

Semaglutide can help regulate blood sugar levels and decrease long-term health complications related to diabetes.

Practitioners can use semaglutide to manage blood sugar levels and reduce diabetes-related complications.

SELECT demonstrated a significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established atherosclerotic cardiovascular disease, independent of diabetes status.

Semaglutide may significantly lower the risk of cardiovascular events in at-risk populations.

GLP-1-based therapies elicit a clinically significant reduction in body weight.

Practitioners can expect GLP-1 therapies to aid in weight loss for patients with type 2 diabetes or obesity.

Tirzepatide reduces appetite and aids in weight reduction management.

Tirzepatide may be effective for patients seeking weight loss.

There is a greater emphasis on adjunct pharmacotherapy in the updated guideline, particularly with GLP-1-based agents for weight reduction and improvement of comorbidities.

Healthcare providers should integrate GLP-1-based pharmacotherapy into obesity management strategies.

Binge eating episodes and prevalence reduced following liraglutide and semaglutide.

Practitioners may find liraglutide and semaglutide effective in reducing binge eating behaviors in patients.

PAP+tirzepatide was associated with lower incident PH at 1 year (RR:0.27) and 3 years (RR:0.22), and lower mortality at 1 year (RR:0.14) and 3 years (RR:0.12).

Using tirzepatide in conjunction with PAP may provide superior benefits in reducing PH and mortality for obese patients with OSA.

Compared to PAP+semaglutide, PAP+tirzepatide showed lower incident PH at 1 year (RR:0.51) and 3 years (RR:0.42) and lower all-cause mortality at 1 year (RR:0.41) and 3 years (RR:0.33).

Tirzepatide may offer enhanced benefits over semaglutide for reducing PH and mortality in obese patients with OSA on PAP.